DeZwarteRidder 30 augustus 2018 19:38 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 Esperite secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologiesTotal investment can reach EUR 7.25 million upon exercise of share subscription warrantsAmsterdam, The Netherlands - 19 June 2018Transaction highlights Potential financing of up to EUR 5 million through private placements of convertible notes with share subscription warrants attached over the next 24 months, subject to fulfilment of certain conditions Upon the exercise of all share subscription warrants, the total investment can reach EUR 7.25 million Subscription by European Select Growth Opportunities Fund, based in Australia Esperite to convene a general meeting to present the details of the financing to its shareholders and to propose to approve the issuance of tranches of convertible notes with share subscription warrants attached Proceeds to be used to support Esperite's commercial activities and development of innovative technologies in the field of genetics, data-driven medicine, regenerative medicine and Immuno-therapeutic drugsEsperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces today having entered into a second issuance agreement with European Select Growth Opportunities Fund (“ESGO” or the “Investor), following the discussions announced on June 12, 2018 regarding a new external financing (the “Issuance Agreement”).Pursuant to the Issuance Agreement, the Investor has committed to subscribe for an amount of up to EUR 5 million of convertible notes (the “Notes”) with share subscription warrants attached (the “Warrants”), in several tranches over the 24 months following the issuance of the first tranche, subject to the fulfilment of certain conditions, including shareholders' approval by the general meeting of Esperite for the issuance of the Notes and Warrants to the Investor. The issuance of and subscription to the Notes and Warrants will be structured through the issuance by Esperite to the Investor of tranche warrants (the "Tranche Warrants"), whose characteristics are described in Appendix 1 to this press release.This new external financing is in addition to the earlier issuance agreement of up to EUR 9 million (plus EUR 4.05 million in case of exercise of all share subscription warrants) entered into between Esperite and the Investor on March 8, 2017 (the “2017 Issuance Agreement”). Under the 2017 Issuance Agreement, EUR 6.85 million of convertible notes have been issued, leaving EUR 2.15 million still available for issuance by Esperite.Not for distribution in the United States of America, Canada, Australia and Japan2Characteristics of the Notes and of the Warrants The Notes have a principal amount of EUR 10,000 each and will be subscribed for with an initialtranche of EUR 300,000 and subsequent tranches of EUR 250,000 (unless increased ordecreased upon mutual consent of Esperite and the Investor). The Notes bear no interest andhave a maturity of 12 months from their issuance. During their term, the Investor may request toconvert any or all of the Notes at a price equal to the lowest daily VWAP over the 10 consecutivetrading days preceding the conversion request, minus a 6% discount (it being specified that daysduring which the Investor will have traded shares on the market will be excluded). Upon such conversion request, Esperite shall have the option to remit at its discretion, cash,shares in the capital of the Company or a combination of both. The Warrants have a maturity of 5 years from their issuance date and will be immediatelydetached from the Notes. Each Warrant will give right to subscribe for 1 new share in Esperite at aprice equal to 115% of the lowest daily VWAP over the 10 consecutive trading days preceding therequest from Esperite to issue the applicable tranche. Esperite can request the Investor to subscribe a tranche every 3 months (or earlier to the extentall outstanding Notes have been converted or redeemed). The Investor can subscribe to tranches at its discretion within the first EUR 2.5 million of the EUR5 million commitment. Furthermore, the terms of the Notes and Warrants include: (i) customary business and compliancecovenants; (ii) early redemption events; and (iii) standard anti-dilution mechanisms. Detailed terms and conditions of the Notes and the Warrants are set forth in Appendix 1 to thispress release.At the next general meeting, Esperite will present the details of the new external financing to itsshareholders and the shareholders will be asked to resolve to approve the issuance of the Notes andWarrants. Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 30 augustus 2018 19:39 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 Terms and conditions regarding the issuance oftranche warrants for the subscription of convertible noteswith share subscription warrants attachedLegal framework of the transactionOn June 18, 2018, Esperite N.V. ("Esperite") and European Select Growth Opportunities Fund, afund based in Australia (the "Investor") entered into an issuance agreement pursuant to which theInvestor has agreed to subscribe for up to 500 tranche warrants (the "Tranche Warrants") pursuantto which the Investor has committed to subscribe for up to 500 convertible notes, with a principalamount of EUR 10,000 each (the "Notes"), with share subscription warrants attached (the"Warrants”) over the 24 months following the issuance of the first tranche, subject to the fulfilment ofcertain conditions (as set out below), including shareholders' approval to be obtained at the nextgeneral meeting.Main characteristics of the Tranche WarrantsDuring a period of 24 months as from the issuance of the first tranche, Esperite may request (a“Request”) the exercise of Tranche Warrants and the issuance of Notes with Warrants attached intranches of EUR 300,000 (first tranche) and EUR 250,000 (subsequent tranches) each, upon theearlier of (i) the full conversion into shares and/or redemption in cash of all outstanding Notes and (ii)the 3-month anniversary of the issuance of the previous tranche of Notes, provided that the followingconditions are satisfied:(i) no more than 24 months shall have expired from the issuance of the first tranche;(ii) (a) all the Notes that had been issued in connection with a previous tranche have beenconverted into shares and/or repaid in full (including the Notes issued under the existingfinancing agreement dated March 8, 2017) or (b) more than three months have elapsed sincethe last Tranche Warrant exercise date;(iii) no material adverse change shall have occurred;(iv) no event that constitutes an event of default and no triggering event that would constitute anevent of default if not cured during the applicable cure period, if any, shall be in existence;(v) no suspension of the trading of the shares on Euronext (other than intra-day suspension at therequest of Euronext Amsterdam under Euronext rules) shall have occurred over the 90preceding calendar days (including the date of the sending of the Request);(vi) the Issuer shall have at least:? 2 times coverage of shares (based on the Conversion Price) authorized, available andapproved for issuance to the Investor upon conversion of the maximum amount ofNotes to be issued for the applicable Tranche, increased, as the case may be, by theamount of any other outstanding Notes; and? 1 time coverage of shares authorized, available and approved for issuance to theInvestor upon exercise of the maximum number of Warrants to be issued for theapplicable tranche;(vii) taking into account the Notes to be issued to the Investor under the requested tranche, theInvestor shall not hold more than EUR 750,000 of aggregate principal amount of Notes;(viii) the closing price and the daily volume weighted average price on each of the 5 precedingtrading days shall be at least equal to EUR 0.70 (subject to adjustments resulting from shareconsolidation or share split); and(ix) the average daily value traded of the shares over the 10 preceding trading days shall be atleast equal to EUR 20,000,and the Investor shall have the obligation to subscribe for such tranches of Notes with Warrantsattached. The Investor may waive these conditions at its sole discretion, for an additionalconsideration.Not for distribution in the United States of America, Canada, Australia and Japan4The Investor shall also have the right to exercise Tranche Warrants at its sole and exclusivediscretion in respect of the first 250 Tranche Warrants (i.e. up to an aggregate principal amount ofEUR 2.5 million). The remaining 250 Tranche Warrants shall only be exercisable upon request ofEsperite.The Tranche Warrants are not transferable, except that the Investor may transfer or assign all or partof its Tranche Warrants to one or more of its affiliates. The Tranche Warrants will not be admitted totrading on any financial market.Main characteristics of the NotesThe Notes have a nominal value of EUR 10,000 each and will be subscribed at 99.5% of suchnominal value. The Notes bear no interest and have a maturity of 12 months from their respectiveissuance date.Each Note gives its holders a conversion right to receive, at Esperite’s discretion (i) cash, (ii) ordinaryshares, or (iii) a combination of cash and ordinary shares (a "Conversion"). Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 30 augustus 2018 19:41 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 If Esperite chooses to remit cash, the corresponding amount shall be equal to:A = (Nv / Cp) * VWAP"A": cash amount payable to the Note holder;"Nv": nominal value of the Note (EUR 10,000);"Cp": "Conversion Price", equal to 94% of the lowest daily volume weighted average price of theGroup's share during the relevant pricing period;"VWAP": the volume weighted average price of the Group's share on the Conversion date.If Esperite chooses to remit new and/or existing shares, the corresponding number of shares shall beequal to:N = Nv / Cp"N": number of new and/or existing shares to be remitted to the Note holder;"Nv": nominal value of the Note (EUR 10,000);"Cp": the applicable Conversion Price.At maturity or upon the occurrence of any event of default, any Note for which no Conversion hasoccurred shall be redeemed at par in cash by the Group.The Notes may be freely transferred or assigned by the Investor to one or more of its affiliates andmay not be transferred or assigned to any other third party without the prior written consent ofEsperite. The Notes will not be admitted to trading on any financial market.Main characteristics of the WarrantsThe number of Warrants to be issued under each tranche will be such that, multiplied by their strikeprice (determined as described below), the resulting amount shall be equal to 45% of the principalamount of the tranche, i.e. for the first tranche of EUR 300,000, an amount of EUR 135,000, and foreach subsequent tranche of EUR 250,000, an amount of EUR 112,500.The Warrants shall be immediately detached from the Notes. They may be freely transferred orassigned by the Investor to one or more of its affiliates and may not be transferred or assigned to anyother third party without the prior written consent of Esperite. The Warrants shall have a maturity of 5years from their respective issuance date (the "Exercise Period"). Each Warrant will give right to itsholder, during the Exercise Period, to subscribe 1 new share of Esperite, subject to customary antidilutionprotection.Not for distribution in the United States of America, Canada, Australia and Japan5The strike price of the Warrants will be equal to 115% of Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 30 augustus 2018 19:42 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 The strike price of the Warrants will be equal to 115% of the lowest daily volume weighted average price of the share over the 10 consecutive trading days preceding the Request from Esperite to issue a tranche (or the Tranche Warrant exercise date, in case of Tranche Warrants exercised at the discretion of the Investor). The Warrants will not be admitted to trading on any financial market.New shares resulting from Conversion of Notes or exercise of WarrantsThe new shares issued upon Conversion of Notes or exercise of Warrants will be admitted to trading on Euronext as from their issuance, will carry immediate and current dividend rights and will be fully assimilated to and fungible with the existing shares (ISIN code NL0009272137).Commitment of the InvestorUntil the latest of (i) the 24-month anniversary of the issuance of the first tranche and (ii) the full conversion into shares and/or redemption of all the outstanding Notes, the Investor has committed: not to hold at any time a number of shares higher than 17% of the outstanding number of shares of Esperite; and not to request any representation on the board of directors of Esperite. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 30 augustus 2018 20:25 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 ‘Remember, buy in september’ :-) Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 31 augustus 2018 10:48 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 European Select Growth Opportunities Fund - Esperite N.V. - ZutphenHieronder vindt u informatie uit het register substantiële deelnemingen en bruto shortposities. Deze informatie is door de organisatie verstrekt. Datum meldingsplicht 29 aug 2018 Meldingsplichtige European Select Growth Opportunities Fund Uitgevende instelling Esperite N.V. Inschrijving handelsregister 27187482 Plaats Zutphen==================================================================Verdeling in aantallen (longpositie)Soort aandeel Aantal aandelen Aantal stemmen Kapitaalbelang Stemrecht Wijze van beschikken AfwikkelingGewoon aandeel 90,00 90,00 Reëel Reëel Rechtstreeks Warrant 6.376.445,00 6.376.445,00 Potentieel Potentieel Rechtstreeks Converteerbare note 1.115.241,00 1.115.241,00 Potentieel Potentieel Rechtstreeks =================================================================Procentuele verdeling (longpositie)Soort aandeel Totale deelneming Rechtstreeks reëel Rechtstreeks potentieel Middellijk reëel Middellijk potentieelKapitaalbelang 28,39 % 0,00 % 28,39 % 0,00 % 0,00 %Stemrecht 28,39 % 0,00 % 28,39 % 0,00 % 0,00 %Datum laatste update: 31 augustus 2018 Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 31 augustus 2018 11:06 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 Van ca 25 miljoen aandelen die ESGOF al heeft gekregen, heeft ESGOF er dus nog 90 stuks over....!!!En er komen nog ca 50 a 60 miljoen aandelen bij...... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 31 augustus 2018 11:15 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 De aanzienlijke vooruitgang in de jaarrekening wordt nog niet beloond door de aandeelhouders. Eerst moet er meer zekerheid komen. De jaarrekening is dus bijna klaar, maar nog niet helemaal. Aanbevelingen 0 ” Quote Reageren Niet oké
DeZwarteRidder 31 augustus 2018 11:23 auteur info DeZwarteRidder Lid sinds: 29 jun 2012 Laatste bezoek: 12 feb 2025 Aanbevelingen Ontvangen: 24121 Gegeven: 10539 Aantal posts: 102.036 quote:Bakker88 schreef op 31 augustus 2018 11:15:De aanzienlijke vooruitgang in de jaarrekening wordt nog niet beloond door de aandeelhouders. Eerst moet er meer zekerheid komen. De jaarrekening is dus bijna klaar, maar nog niet helemaal.Je bent een grapjas of je kan de toekomst voorspellen..... Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.